One pack, three or four prescribing departments. Inj Leuprolide 3.75 goes to urology for advanced prostate cancer, to gynecology for endometriosis and for the anemia that fibroids cause, and on some Indian labels to pediatric endocrinology as well. That spread is unusual for a single stock-keeping unit, and it is worth knowing before you forecast demand for one specialty. Leuprolide acetate 3.75 mg injection also sits apart from the rest of the hormone range on the factory side, because the vial does not hold a plain powder. It holds a polymer depot built to release a drug for a month from one injection.

Mechanism of Action of Leuprolide Acetate and the First Two Weeks

Here is the part most product listings skip. Leuprolide is a GnRH agonist, and for the first two weeks, it does the opposite of what the therapy is for. The natural hormone reaches the pituitary in pulses. A depot injection delivers it continuously instead, and the gland answers the only way it can, by releasing more luteinizing hormone and follicle-stimulating hormone. Testosterone and estradiol climb above where they started. Only after the receptors downregulate does output fall away.

That is the whole mechanism of action of leuprolide in one sentence: stimulate hard enough, for long enough, and the switch turns off. The approved labeling puts numbers on the second half. Hormone levels drop within two to four weeks of the first dose, and in one study, 160 of 162 men were below the castrate threshold of 50 ng per dL by day 28.

The early surge is not a footnote. The labeling records a temporary worsening of symptoms during the first few weeks, including a short increase in bone pain, and a worsening of existing hematuria and urinary tract obstruction in the first week. Isolated cases of ureteral obstruction and spinal cord compression appear there, too. Clinicians plan around this window, which is why an antiandrogen often covers the first weeks in prostate cancer. For women, estradiol can rise in the weeks after the first injection before it falls.

Leuprolide Acetate Injection Uses and the Time Limit on Each One

The approved Leuprolide Acetate Depot for Injection 3.75 mg uses come with something unusual attached: a stopwatch. Most injectables are dosed until the clinician decides to stop. Two of these indications carry a hard ceiling in the labeling, because the bone loss discussed further down accumulates with exposure. Endometriosis treatment is limited to six months. Fibroid treatment before surgery runs up to three months, given with iron. Retreatment for endometriosis may be considered once, as a second six-month course alongside norethisterone acetate tablets, and the labeling does not recommend retreatment with leuprolide alone.

For the prostate cancer indication, leuprolide acetate injection is used in palliative care of advanced disease, where suppressing testosterone slows a tumor that depends on it. The same logic drives hormone blockade elsewhere in oncology, which is why distributors carrying this vial often stock letrozole tablets as well. On the gynecology side, buyers usually hold an oral option such as dienogest and ethinylestradiol tablets for patients who do not need a depot.

Inj Leuprolide 3.75 Carries More Polymer Than Drug

Read the composition of the 3.75 mg depot, and the ratio stands out. The drug chamber holds 3.75 mg of leuprolide acetate, 0.65 mg of purified gelatin, 6.6 mg of D-mannitol, and 33.1 mg of a copolymer of lactic and glycolic acids. The carrier outweighs the active ingredient by close to nine to one. The diluent side adds carboxymethylcellulose sodium, mannitol, polysorbate 80, water for injection, and acetic acid for pH control.

That copolymer is the product. Those 33.1 mg form the microspheres that hold the peptide and hand it over over a month as the polymer breaks down. Making this is a different job from filling a lyophilized antibiotic. A plant needs sterile microsphere production, control of particle size, and release rate validation batch after batch, because a depot that empties in ten days or forty days both fail. The short supplier list at this strength follows from that, and it is the first thing to establish with any partner quoting on leuprolide acetate 3.75 mg injection.

Leuprolide Acetate Injection 1mg or the 3.75 mg Depot

These two get ordered interchangeably by mistake, and they are not substitutes. Leuprolide acetate injection 1mg is a daily subcutaneous dose drawn from a 2.8 mL multiple-dose vial at 5 mg per mL. The patient or carer injects 0.2 mL every day. The depot replaces about thirty of those injections with one intramuscular dose a month, which is the reason it dominates the market even at a higher unit price.

The practical difference for a distributor is adherence, not pharmacology. A patient who misses daily injections loses suppression quietly. A patient on a monthly depot either attends the appointment or does not, and the gap is visible in the clinic diary.

Mixing the Depot and Why It Cannot Wait

Suppose a nurse in a day care unit prepares the dose, then the patient is called away for ten minutes. With most injectables, the syringe waits. Not this one. The suspension settles quickly once mixed, so the labeling calls for the entire contents to go in immediately, and the product carries no preservative, which means an unused portion gets discarded rather than kept.

The rest of the handling sequence is short and worth printing on the carton insert:

• Inspect the powder before mixing, and do not use it if it has clumped or caked.
• Hold the syringe upright and push the plunger slowly, over six to eight seconds, until the first stopper reaches the blue line.
• Mix until the suspension looks uniform and milky, with no clumps against the barrel.
• Inject the full dose straight away, intramuscularly, and rotate the site between monthly doses.
• Store at 25°C, with excursions permitted between 15 and 30°C.

Leuprolide Injection Side Effects and the Bone Density Limit

Almost everyone gets hot flashes. In the endometriosis trials, about 84 percent of women on the 3.75 mg dose reported hot flashes or sweats, and about 73 percent of the fibroid patients did. This is the predictable result of removing estrogen, not an idiosyncratic reaction, and it shapes how the course is explained to a patient. Headache was reported by about 32 percent, vaginitis by about 28 percent, depression or emotional lability by about 22 percent, and general pain by about 19 percent.

Bone density is the finding that sets the time limits. Vertebral bone density measured by DEXA fell by an average of 3.2 percent over six months of treatment for endometriosis. In fibroid patients, trabecular density fell by a mean of 2.7 percent after three months. The add-back study is the clearest comparison: at week 52, the lumbar spine was down about 6.3 percent with leuprolide alone, against roughly 1.0 to 1.1 percent when norethindrone acetate was given with it. Treatment beyond those ceilings, or in a patient who already carries risk factors for bone loss, is not recommended in the labeling.

Two more Leuprolide Acetate Depot for Injection 3.75 mg side effects belong on any training sheet. Menstruation usually stops during therapy and returns some weeks after the last dose. Blood sugar can shift, which matters for diabetic patients already on treatment. The product is contraindicated in women who are or may become pregnant; it carries pregnancy category X, and pregnancy must be excluded before the first injection.

Leuprolide 3.75 mg Injection Price in India

The leuprolide acetate injection price is MRP is ₹2,892 per pack. Presentation is what moves it most, because a dual chamber prefilled syringe and a vial with a separate diluent ampoule do not cost the same to fill or to assemble, and the Leuprolide Acetate Depot for Injection 3.75 mg price quoted to a distributor reflects whichever format ships.

The depot itself carries the rest of the cost, since sterile microsphere handling and release rate testing sit in the base, whatever the pack looks like. Batch pricing then depends on the number of packs. Send your monthly requirement for inj leuprolide 3.75, with the pack format and the destination market, and the team will come back with current rates.

Leuprolide Acetate Depot for Injection 3.75 mg Manufacturer in India

Torso Healthcare is a WHO GMP-certified injectable manufacturer based in Baddi, Himachal Pradesh, supplying hospitals, distributors, and franchise partners across India and export markets. The hormone range already covers products such as hydroxyprogesterone injection, and the wider approach to hormonal products manufacturing carries the segregation and cleaning validation that potent molecules require. Buyers looking for a Leuprolide Acetate Depot for Injection 3.75 mg manufacturer in India usually ask about three things first: whether the depot is made in-house, how the release profile consistency is demonstrated between batches, and what documentation ships with each consignment.

Facility details, dossier support, and batch documentation for the injection manufacturing unit are shared on request, along with standard third-party manufacturing terms.

Distributors, hospitals, and franchise partners sourcing inj leuprolide 3.75 in bulk, or planning their own label hormone line around it, can share your pack specification with the quantity, format, and destination market, and Torso Healthcare will reply with current rates and lead times.

Composition, indications, duration limits, bone density findings, handling, and safety details on this page follow the FDA prescribing information for leuprolide acetate depot 3.75 mg and the daily injection labeling for the 5 mg per mL presentation.

Frequently Asked Questions

Why do symptoms sometimes get worse in the first two weeks?

Because the drug stimulates before it suppresses. The first injection pushes LH and FSH up, which raises testosterone or estradiol above baseline for a short period. The labeling records transient worsening of symptoms in the first few weeks, including bone pain and urinary obstruction, before levels fall.

How soon does testosterone reach castrate levels?

Within two to four weeks of starting treatment. In the study cited in the labeling, 160 of 162 patients, or 98.8 percent, were below the castrate threshold of 50 ng per dL on day 28. Suppression then holds as long as monthly dosing continues.

Can the 3.75 mg depot be given subcutaneously?

No. This depot is labeled for intramuscular injection once a month. Other leuprolide products are designed for subcutaneous use, including the daily 1 mg injection, so the route belongs to the specific formulation and the two are not interchangeable.

Is leuprorelin the same molecule as leuprolide?

Yes. Leuprorelin and leuprolide are two accepted names for the same peptide, which is why Indian cartons and international references sometimes differ. Check the strength and the depot interval rather than the name when matching a product to a tender.

Does every patient need add back therapy?

No. The labeling specifies norethindrone acetate 5 mg daily for the single retreatment course in endometriosis, and iron alongside treatment for fibroid-related anemia. The prescribing clinician decides on add back for the first course based on the individual patient.

Can the pack be supplied under our own brand name?

Yes. The depot is available for third-party manufacturing and franchise supply with your brand name and carton artwork, subject to the product being in the current manufacturing range. Batch documentation, including a certificate of analysis, travels with each consignment.

Disclaimer: This page is intended for pharmaceutical businesses, trade buyers, and healthcare professionals as product reference information only. It is not an advertisement to the public, not medical advice, and not a recommendation for treatment. Leuprolide acetate depot is a prescription medicine and must be prescribed and administered only under qualified medical supervision.